Sp1038
EARLY CHRONIC PANCREATITIS OR DISORDER OF THE BRAIN-GUT AXIS
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
This session will cover a variety of disorders causing chronic abdominal pain which may be very difficult to differentiate. LIVE STREAM SESSION
This session will cover a variety of disorders causing chronic abdominal pain which may be very difficult to differentiate. LIVE STREAM SESSION
Presenter
Tracks
Related Products
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
IDENTIFICATION OF NEUROPATHIC PAIN USING CLINICAL SURROGATES BASED ON PANCREATIC QUANTITATIVE SENSORY TESTING (P-QST) IN PATIENTS WITH CHRONIC PANCREATITIS.
BACKGROUND Chronic pancreatitis (CP) may severely impact quality of life (QoL). Since CP is a chronic condition, multiple assessments of QoL are required to obtain a thorough understanding of its impact on patients. Such studies are currently lacking…
